Barinthus Bio Reports Positive Progress in Celiac Disease Immunotherapy Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Source: Newsfilter
- Clinical Trial Progress: Barinthus Bio's VTP-1000 demonstrated good tolerability in the Phase 1 trial for celiac disease, with no treatment-related serious adverse events reported in the single ascending dose (SAD) portion, indicating both safety and potential efficacy of the therapy.
- Significant Pharmacological Effects: Among the 18 patients in the SAD phase, a dose-dependent pharmacological effect was observed, suggesting that the therapy can effectively stimulate immune responses, thereby laying the groundwork for future multiple dosing studies that may offer new treatment options for celiac disease patients.
- Anticipated Follow-Up Research: The ongoing multiple ascending dose (MAD) phase is expected to yield data in the second half of 2026, which will provide critical insights for further validating the efficacy of VTP-1000 and optimizing treatment regimens, potentially transforming the treatment landscape for celiac disease.
- Substantial Market Potential: With celiac disease affecting approximately 80 million people globally and no approved treatments currently available, the successful development of VTP-1000 could address this high unmet need, presenting significant commercial value and societal impact.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like BRNS with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on BRNS
Wall Street analysts forecast BRNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRNS is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.738
Low
4.00
Averages
4.00
High
4.00
Current: 0.738
Low
4.00
Averages
4.00
High
4.00
About BRNS
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Receives Upgrade to Buy: Implications for the Stock
Zacks Rank Upgrade: Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which could lead to increased stock prices.
Earnings Estimate Revisions: The Zacks Consensus Estimate for the company has risen by 1.1% over the past three months, reflecting analysts' growing confidence in its earnings potential.
Investment Strategy: The Zacks rating system, which categorizes stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.
Market Positioning: The upgrade places Barinthus Biotherapeutics in the top 20% of Zacks-covered stocks, suggesting it is well-positioned for potential market-beating returns in the near term.
Continue Reading
Barinthus Bio Reports Positive Progress in Celiac Disease Immunotherapy Trial
- Clinical Trial Progress: Barinthus Bio's VTP-1000 demonstrated good tolerability in the Phase 1 trial for celiac disease, with no treatment-related serious adverse events reported in the single ascending dose (SAD) portion, indicating both safety and potential efficacy of the therapy.
- Significant Pharmacological Effects: Among the 18 patients in the SAD phase, a dose-dependent pharmacological effect was observed, suggesting that the therapy can effectively stimulate immune responses, thereby laying the groundwork for future multiple dosing studies that may offer new treatment options for celiac disease patients.
- Anticipated Follow-Up Research: The ongoing multiple ascending dose (MAD) phase is expected to yield data in the second half of 2026, which will provide critical insights for further validating the efficacy of VTP-1000 and optimizing treatment regimens, potentially transforming the treatment landscape for celiac disease.
- Substantial Market Potential: With celiac disease affecting approximately 80 million people globally and no approved treatments currently available, the successful development of VTP-1000 could address this high unmet need, presenting significant commercial value and societal impact.
Continue Reading